43 results on '"Wu, Zekui"'
Search Results
2. Data from MUC1 Oncoprotein Regulates Bcr-Abl Stability and Pathogenesis in Chronic Myelogenous Leukemia Cells
3. Supplementary Figure 6 from Direct Targeting of the Mucin 1 Oncoprotein Blocks Survival and Tumorigenicity of Human Breast Carcinoma Cells
4. Supplementary Figure 5 from MUC1 Oncoprotein Regulates Bcr-Abl Stability and Pathogenesis in Chronic Myelogenous Leukemia Cells
5. Data from Direct Targeting of the Mucin 1 Oncoprotein Blocks Survival and Tumorigenicity of Human Breast Carcinoma Cells
6. Supplementary Figure 4 from MUC1 Oncoprotein Regulates Bcr-Abl Stability and Pathogenesis in Chronic Myelogenous Leukemia Cells
7. Supplementary Figure 3 from MUC1 Oncoprotein Regulates Bcr-Abl Stability and Pathogenesis in Chronic Myelogenous Leukemia Cells
8. Supplementary Figure 2 from MUC1 Oncoprotein Regulates Bcr-Abl Stability and Pathogenesis in Chronic Myelogenous Leukemia Cells
9. Supplementary Figure 6 from MUC1 Oncoprotein Regulates Bcr-Abl Stability and Pathogenesis in Chronic Myelogenous Leukemia Cells
10. Supplementary Figure 5 from Direct Targeting of the Mucin 1 Oncoprotein Blocks Survival and Tumorigenicity of Human Breast Carcinoma Cells
11. Supplementary Figure 1 from MUC1 Oncoprotein Regulates Bcr-Abl Stability and Pathogenesis in Chronic Myelogenous Leukemia Cells
12. Supplementary Figure 7 A-B from Direct Targeting of the Mucin 1 Oncoprotein Blocks Survival and Tumorigenicity of Human Breast Carcinoma Cells
13. Supplementary Figure 1A-C from Direct Targeting of the Mucin 1 Oncoprotein Blocks Survival and Tumorigenicity of Human Breast Carcinoma Cells
14. Supplementary Figure 4 from Direct Targeting of the Mucin 1 Oncoprotein Blocks Survival and Tumorigenicity of Human Breast Carcinoma Cells
15. Supplementary Materials, Figure Legends 1-7 from Direct Targeting of the Mucin 1 Oncoprotein Blocks Survival and Tumorigenicity of Human Breast Carcinoma Cells
16. Supplementary Figure 2 from Direct Targeting of the Mucin 1 Oncoprotein Blocks Survival and Tumorigenicity of Human Breast Carcinoma Cells
17. Supplementary Figure 3 from Direct Targeting of the Mucin 1 Oncoprotein Blocks Survival and Tumorigenicity of Human Breast Carcinoma Cells
18. MUC1-C oncoprotein suppresses reactive oxygen species–induced terminal differentiation of acute myelogenous leukemia cells
19. Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma
20. Fusion of dendritic cells with multiple myeloma cells results in maturation and enhanced antigen presentation
21. Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells
22. Induction of Antitumor Immunity Ex Vivo Using Dendritic Cells Transduced With Fowl Pox Vector Expressing MUC1, CEA, and a Triad of Costimulatory Molecules (rF-PANVAC)
23. Generation of Tumor-specific T Lymphocytes Using Dendritic Cell/Tumor Fusions and Anti-CD3/CD28
24. CT-011, Anti-PD-1 Antibody, Enhances Ex-Vivo T Cell Responses to Autologous Dendritic/Myeloma Fusion Vaccine Developed for the Treatment of Multiple Myeloma.
25. A Comparative Analysis of Immune Reconstitution Following Reduced Intensity Conditioning with CAMPATH-1H and Total Lymphoid Irradiation/Anti-Thymocyte Globulin Prior to Allogeneic Stem Cell Transplantation.
26. Dendritic Cell Tumor Fusion Vaccination in Conjunction with Autologous Transplantation for Multiple Myeloma.
27. Direct Targeting of the Mucin 1 Oncoprotein Blocks Survival and Tumorigenicity of Human Breast Carcinoma Cells
28. Immunomodulatory Effects of Vitamin D: Implications for the Prevention and Treatment of Graft Versus Host Disease
29. Fusion Cell Vaccination in Conjunction with Stem Cell Transplantation Is Well Tolerated, Induces Anti-Tumor Immunity and Is Associated with Responses in Patients with Multiple Myeloma
30. Adoptive T Cell Therapy Using Educated T Cells Generated by the Sequential Stimulation with DC/Tumor Fusion Cells and Anti-CD3CD28
31. Fusions of Dendritic Cells with Breast Carcinoma Stimulate the Expansion of Regulatory T Cells while Concomitant Exposure to IL-12, CpG Oligodeoxynucleotides, and Anti-CD3/CD28 Promotes the Expansion of Activated Tumor Reactive Cells
32. MUC1 Oncoprotein Regulates Bcr-Abl Stability and Pathogenesis in Chronic Myelogenous Leukemia Cells
33. Targeting MUC1 as a Marker for Myeloid Leukemia Stem Cells by DC/AML Fusions.
34. Phase I Study of Vaccination with Dendritic Cell Myeloma Fusions.
35. Vaccination with DC/Multiple Myeloma Fusions in Conjunction with Stem Cell Transplantation.
36. Stimulation of Anti-Tumor Immunity Using Dendritic Cell/Tumor Fusions and Anti-CD3/CD28.
37. Stimulation of Anti-Tumor Immunity Using Dendritic Cells Transduced with Fowl Pox Vector Expressing MUC-1 and Costimulatory Molecules (PANVAC-F).
38. Vaccination with Dendritic Cell Myeloma Fusions Alone or in Conjunction with Stem Cell Transplantation for Patients with Multiple Myeloma.
39. Dendritic Cells Induce MUC1 Expression and Polarization on Human T Cells by an IL-7-Dependent Mechanism
40. Dendritic Cell Myeloma Fusions Stimulate Anti-Tumor Immunity: Results from Pre-Clinical Studies and a Clinical Trial.
41. Fusion Cell Vaccination of Patients with Metastatic Breast and Renal Cancer Induces Immunological and Clinical Responses
42. Fusions of Human Ovarian Carcinoma Cells with Autologous or Allogeneic Dendritic Cells Induce Antitumor Immunity
43. Bone Marrow and Peripheral Blood Dendritic Cells From Patients With Multiple Myeloma Are Phenotypically and Functionally Normal Despite the Detection of Kaposi’s Sarcoma Herpesvirus Gene Sequences
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.